Numis Securities Ltd reissued their buy rating on shares of Circassia Pharmaceuticals PLC (LON:CIR) in a research note released on Tuesday morning. Numis Securities Ltd currently has a GBX 150 ($1.96) target price on the biopharmaceutical company’s stock.
Several other brokerages have also commented on CIR. Barclays PLC initiated coverage on Circassia Pharmaceuticals PLC in a report on Tuesday, June 21st. They issued an overweight rating and a GBX 170 ($2.22) price objective for the company. JPMorgan Chase & Co. cut their price objective on Circassia Pharmaceuticals PLC from GBX 410 ($5.35) to GBX 170 ($2.22) and set an overweight rating for the company in a report on Tuesday, June 21st. Stifel Nicolaus reaffirmed a buy rating and issued a GBX 375 ($4.89) price objective on shares of Circassia Pharmaceuticals PLC in a report on Monday, June 20th. Peel Hunt lowered Circassia Pharmaceuticals PLC to an add rating and cut their price objective for the stock from GBX 509 ($6.64) to GBX 160 ($2.09) in a report on Tuesday, June 21st. Finally, Royal Bank Of Canada lowered Circassia Pharmaceuticals PLC to a sector performer rating and cut their price objective for the stock from GBX 430 ($5.61) to GBX 105 ($1.37) in a report on Tuesday, June 21st. Three investment analysts have rated the stock with a hold rating and three have issued a buy rating to the stock. The company currently has a consensus rating of Buy and a consensus price target of GBX 183.33 ($2.39).
Shares of Circassia Pharmaceuticals PLC (LON:CIR) opened at 94.525 on Tuesday. Circassia Pharmaceuticals PLC has a 12-month low of GBX 81.05 and a 12-month high of GBX 322.90. The firm has a 50 day moving average price of GBX 94.70 and a 200 day moving average price of GBX 178.43. The stock’s market cap is GBX 269.19 million.
Circassia Pharmaceuticals PLC Company Profile
Circassia Pharmaceuticals plc is a specialty biopharmaceutical company focused on allergy and respiratory diseases. The Company operates through three segments: Allergy, which relates to a range of immunotherapy development products for the treatment of allergy; NIOX, which relates to the portfolio of products used to improve asthma diagnosis and management by measuring fractional exhaled nitric oxide (FeNO), and Respiratory, which relates to the portfolio of asthma and chronic obstructive pulmonary disease product candidates.
Receive News & Ratings for Circassia Pharmaceuticals PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Circassia Pharmaceuticals PLC and related companies with MarketBeat.com's FREE daily email newsletter.